Animace načítání

Stránka se připravuje...


Na co čekáte? Nečekejte už ani minutu.
Získejte přístup na tento text ještě dnes. Kontaktujte nás a my Vám obratem uděláme nabídku pro Vás přímo na míru.

Právní předpis byl sestaven k datu 05.03.2026.

Zobrazené znění právního předpisu je účinné od 28.01.2025.


Sdělení Ministerstva zahraničních věcí, kterým se mění a doplňují sdělení Ministerstva zahraničních věcí č. 58/2007 Sb. m. s. a č. 46/2008 Sb. m. s.

19/2025 Sb.
 

Sdělení

INFORMACE

19

XXXXXXX

Xxxxxxxxxxxx zahraničních xxxx,

xxxxxx xx mění x xxxxxxxx sdělení Xxxxxxxxxxxx xxxxxxxxxxxx xxxx č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.
&xxxx;

Xxxxxxxxxxxx xxxxxxxxxxxx xxxx sděluje, že xxx 1. xxxxx 2023 xxxx xxxxxxxxx xxxxxxxxxx XXXXXX xxxxxxxx xxxxxxxxx nového xxxxx Xxxxxxx X - Xxxxxx xxxxxxxxxx látek x metod dopingu xxx xxx 2024 - Xxxxxxxxxxx xxxxxxxx Xxxxxxxxxxx úmluvy xxxxx xxxxxxx ve xxxxxx.

X xxxxx zněním Xxxxxxx X xxxxxxxx souhlas Xxxxxxxxx Xxxxx xxxxxxxxx x prezident republiky xxxxxxxx listinu o xxxxxxx změn Přílohy X Českou xxxxxxxxxx.

Xxxx xxxxx Xxxxxxx X xxxxxxxxx x xxxxxxxx x xxxxxxx x článkem 34 xxxx. 3 Xxxxxx xxx 1. xxxxx 2024, xxx Xxxxxx republiku xxxxxxxxx x xxxxxxxx xxx 18. xxxxxx 2024 x xxxxxxxxx Přílohu X xxx xxx 2023, xxxxxxx od 1. xxxxx 2023, xxxxx xxxxxxxxx v xxxxxxxx xxx Xxxxxx xxxxxxxxx xxx 22. xxxxxx 2023 x xxxx xxxxxxxxx xxx č. 32/2023 Sb. m. s.

Xxxxxxxx xxxxx Xxxxxxx X pro xxx 2024 x xxxx xxxxxxx xx xxxxxxx xxxxxx xx xxxxxxxxx xxxxxxxx.
&xxxx;

Xxxxxxx:

x z. JUDr. Xxxxxx, Xx.X., XX.X., x. x.

xxxxxx ředitel xxxxx právní x xxxxxxxxxx
&xxxx;

Xxxxxxx č. 1

Překlad xxxxxxxxxxx xxxxxxx xx xxxxxxx xxxxxx

Xxxx

Xxxxxx zakázaných xxxxx a xxxxx xxxxxxx xx xxxxxxx Xxxxxxxxxxx xxxxxxxx v xxxxx Světového xxxxxxxxxxxxxxx xxxxxxxx.

Xxxxxx xx xxxxxxxxxx xxxxxxxxxxxx po xxxxxxxxx xxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxxxx Xxxxxxxx antidopingovou xxxxxxxxx (XXXX). Xxxxxx xx xxxxxx xx 1. xxxxx 2024.

Xxxxxxxxx xxxx Xxxxxxx zakázaných látek x metod xxxx xxxxxxxxx XXXX a xxxx xxxxxxxxxx x xxxxxxxxxx a xxxxxxxxxxxxx. X xxxxxxx xxxxxxxxxxx xxxxxxxxxxxxx xxxx xxxxxxxxx x xxxxxxxxxxxx textem xxxxxxxxx xxxxx x xxxxxxxxxx.

Xxxx jsou xxxxxxx xxxxxxx xxxxx xxxxxxxxx x xxxxx Xxxxxxx xxxxxxxxxx látek x xxxxx.

Xxxxxxxx Při soutěži

Pokud XXXX xxx xxxx xxxxx xxxxxxxxxxx xxxx xxxxxx, xx xxxxxx Xxx soutěži x xxxxxx xxxxxxx začínajícím xxxxx před půlnocí (xx 23:59 xxxxx) x xxx xxxxxxxxxxxxx Xxxxxxx, které xx xx Xxxxxxxxx zúčastnit, xx xx konce Xxxxxxx x xxxxxxx xxxxxx Vzorku.

Zakázané xxxxx

Xx xxxxxxx, že xxxx xxxxx xxxx xxxxxx xx xxxxxxxx Při xxxxxxx i Xxxx xxxxxx, xxx je xxxxxxxxxx x Kodexu.

Specifické x Xxxxxxxxxxxx

Xxxxx xxxxxx 4.2.2 Xxxxxxxxx xxxxxxxxxxxxxxx Xxxxxx „xxx účely xxxxxxxx xxxxxx 10 xxxxx xxxxxxx Xxxxxxxx xxxxx Xxxxxxxxxxxx látkami, x xxxxxxxx xxxx xxxxxxxxxx x Seznamu xxxxxxxxxx xxxxx x xxxxx xxxxxxx. Žádná Xxxxxxxx xxxxxx xxxxxx Xxxxxxxxxxx xxxxxxx, xxxxx xxxx v Xxxxxxx xxxxxxxxx označena xxxx Xxxxxxxxxx metoda.“ Podle xxxxxxxxx x xxxxxx „Xxxxxxxxxx látky x Xxxxxxxxxx xxxxxx xxxxxxx x článku 4.2.2 xx xxxxxx xxx xxxxxx xxxxxxxx považovány xx xxxx xxxxxxxx xxxx méně xxxxxxxxxx xxx jiné xxxxxxxxx xxxxx xxxx xxxxxx. Xxx xxxxx x xxxxx x xxxxxx, xxxxx Xxxxxxxxx xxxxxxxxxxxxx xxxx xxxx xxxxxx x jinému xxxxx xxx xx xxxxxxxx xxxxxxxxxxx xxxxxx.“

Xxxxxxxx látky

Podle xxxxxx 4.2.3 Xxxxxx xxxx Návykové xxxxx xxxxxxxxxx jako látky, xxxxx jsou xxxx xxxxxx xxxxxxxx z xxxxxx xxxxxx xxxxxxx xxxxxxxxxx xx společnosti xxxx xxxxx sportu. Xxxx Xxxxxxxx látky xxxx xxxxxxxxxx tyto xxxxx: xxxxxx, xxxxxxxxx (xxxxxx), xxxxxxxxxxxxxxxxxxxxxxxxx (XXXX/„xxxxxx“), xxxxxxxxxxxxxxxxxxx (THC).

S0 XXXXXXXXXXX XXXXX

XXXXXXXX XXXXX (XXX XXXXXXX X XXXX XXXXXX)

Xxxxxxx xxxxxxxx látky x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.

Xxxxxxxxx xxxxxxxxxxxxxx látka, xx xxxxxx xx xxxxxxxxxx xxxxx z xxxxxxxxxxxxx xxxxxx Seznamu x xxxxx xxxx x xxxxxxxx xxxx schválena xxxxxx xxxxxxx xxxxxxxxxxxxx xxxxxxxxxx orgánem xxx xxxxxxx použití x xxxx (např. xxxxxx x xxxxxxxxxxxxx xxxx xxxxxxxxx vývoji xxxx xxxxxxx xxxxx xxx xxxxxxx, xxxxxxxxxx xxxxx, xxxxx xxxxxxxxx xxxxx xxx veterinární použití), xx xxxxxxxx stále.

Tato xxxxx xxxxxxxx mnoho xxxxxxx xxxxx, xxxx xxxx XXX-157, 2,4-xxxxxxxxxxxx (XXX) x xxxxxxxxxx xxxxxxxxx (např. Xxxxxxxxxxx x Xxxxxxxxxx).

X1 ANABOLICKÉ XXXXX

XXXXXXXX XXXXX (PŘI XXXXXXX X XXXX XXXXXX)

Xxxxxxx xxxxxxxx látky x xxxx xxxxx xxxx Xxxxxxxxxxxx látky.

Anabolické xxxxx xxxx xxxxxxxx.

X1.1. XXXXXXXXXX XXXXXXXXXX STEROIDY (XXX)

Xxx xxxxxxxxx podání, xxxx jiné xxxxxx:

1-xxxxxxxxxxxxxx (5ɑ-xxxxxxx-1-xx-3ß, 17ß-xxxx)

&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;

&xxxx;•&xxxx;

xxxxxxxxxx

1-xxxxxxxxxxxxxx (5ɑ-androst-1-en-3,17-dion)

 •

furazabol (17ɑ-xxxxxx [1,2,5]xxxxxxxxxx[3’,4’:2,3]-5ɑ-xxxxxxxxx-17ß-xx)

1-xxxxxxxxxxx (3ɑ-xxxxxxx-5x-xxxxxxx-1-xx-17-xx)

&xxxx;•

xxxxxxxxx

1-xxxxxxxxxxxxxx (3ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-17-xx)

&xxxx;•

xxxxxxxxxx

1-xxxxxxxxxxx (17ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-3-xx)

&xxxx;•

xxxxxxxxxx

4-xxxxxxxxxxxxxx (androst-4-en-3ß, 17ß-xxxx)

&xxxx;•

xxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxxxxxxxxxxx-1,4-xxxx-3-xx)

4-xxxxxxxxxxxxxxxxxx(4,17ß-xxxxxxxxxxxxxxxx-4-xx-3-xx)

&xxxx;•

xxxxxxxxx

5-xxxxxxxxxxxxxx (androst-5-en-3,17-dion)

 •

metandriol

7ɑ-hydroxy-DHEA

 •

metasteron (17β-xxxxxxx-2α,17α-xxxxxxx-5α-xxxxxxxxx-3-xx)

7ß-xxxxxxx-XXXX

&xxxx;•

xxxxx-1-xxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxx-5ɑ-xxxxxxx-1-xx-3-xx)

7-xxxx-XXXX

&xxxx;•

xxxxxxxxxxxxxx

11ß-xxxxx-19-xxxxxxxxxxxxxx

&xxxx;•

xxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4,9-xxxx-3-xx)

17ɑ-xxxxxxxxxxxxxxxxxxx (xxxxxxx)

&xxxx;•

xxxxxxxxxxxxxxxxxxx (17ß-hydroxy-17ɑ-metylestr-4-en-3-on)

19-norandrostenediol (xxxx-4-xx-3,17-xxxx)

&xxxx;•

xxxxxxxxxxxxxxxx

19-xxxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx)

&xxxx;•

xxxxxxxxxx (xxxxxxxxxxxxxx, 17ß-hydroxy-17ɑ-methylestra-4,9,11-trien-3-on)

Androst-4-en-3,11,17-trion(11-ketoandrostenedion, xxxxxxxxxxxx)

&xxxx;•

xxxxxxxxx

xxxxxxxxxxxxx (5ɑ-dihydrotestosteron, 17ß-xxxxxxx-5ɑ-xxxxxxxxx-3-xx)

&xxxx;•

xxxxxxxxx (19-xxxxxxxxxxxxxx)

xxxxxxxxxxxxxx (xxxxxxx-5-xx-3ß,17ß-xxxx)

&xxxx;•

xxxxxxxxxx

xxxxxxxxxxxxxx (androst-4-en-3,17-dion)

 •

norklostebol (4-xxxxxx-17β-xx-xxxx-4-xx-3-xx)

xxxxxxxxxx

&xxxx;•

xxxxxxxxxxxxx

xxxxxxxx

&xxxx;•

xxxxxxxx

xxxxxxx (androsta-1,4-dien-3,17-dion)

 •

oxandrolon

calusteron

 •

oxymesteron

klostebol

 •

oxymetolon

danazol ([1,2]xxxxxxx[4’,5’:2,3]xxxxxx-4-xx- 20-xx-17ɑ-xx)

&xxxx;•

xxxxxxxxx (dehydroepiandrosteron, XXXX, 3β-xxxxxxxxxxxxxx-5-xx-17-xx)

xxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-chloro- 17ß-xxxxxxx-17ɑ-xxxxxxxxxxxxx-1,4-xxxx-3-xx)

&xxxx;•

xxxxxxxxxxx (17β-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxx)

xxxxxxxxxxxxxxxxxxxxxx (17ɑ-xxxxxx-5ɑ-xxxxxxx-2-xx-17ß-xx x 17ɑ-xxxxx-5ɑ- xxxxxxx-3-xx-17ß- ol)

 •

quinbolon

dimetandrolon (7ɑ,11ß-xxxxxxx-19-xxxxxxxxxxxxxx)

&xxxx;•

xxxxxxxxxx

xxxxxxxxxxx

&xxxx;•

xxxxxxxxx

xxxxxxxxxxxxxx (3β-hydroxy-5α-androstan-17-on)

 •

testosteron

epi-dihydrotestosteron (17β-xxxxxxx-5β-xxxxxxxxx-3-xx)

&xxxx;•

xxxxxxxxxxxxxxxxxxx (17-xxxxxxx-18x-xxxx-19-xxx-17ɑ-xxxxxx-4,9,11-xxxxx-3-xx)

xxxxxxxxxxxxxx

&xxxx;•

xxxxxxx

xxxxxxxxxxxx (19-norpregna-4-en-17α-ol)

 •

trenbolon (17β-hydroxyestr-4,9,11-trien-3-on)

fluoxymesteron

 •

trestolon (7ɑ-xxxxx-19-xxxxxxxxxxxxxx, XXXX)

x další xxxxx x podobnou xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx účinky.

S1.2. XXXXXXX ANABOLICKÉ LÁTKY

Mimo xxxx xxxxxx:

Xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx modulátory xxxxxxxxxxxxx xxxxxxxxx [XXXX, xxxx. xxxxxxx, enobosarm (xxxxxxx), XXX-4033 (ligandrol), XXX140, S-23 a XX-11], xxxxxxx x xxxxxxxxxx.

X2 XXXXXXXXX XXXXXXX, XXXXXXX FAKTORY, PŘÍBUZNÉ XXXXX X XXXXXXXX

XXXXXXXX XXXXX (XXX XXXXXXX X XXXX XXXXXX)

Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx jsou Xxxxxxxxxxxx xxxxx.

Xxxxxxxxxxx xxxxx x další látky x xxxxxxxx chemickou xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx xxxxxx xxxx xxxxxxxx.

X2.1. XXXXXXXXXXXXX (XXX) X XXXXX OVLIVŇUJÍCÍ XXXXXXXXXXX

Xxxx xxxx xxxxxx:

X2.1.1 Xxxxxxxx erytropoetinových receptorů, xxxx. xxxxxxxxxxxx (dEPO); xxxxxxxxxxxxx (XXX); xxxxxxxxxx xxxxxxxx xx EPO, [xxxx. EPO-Fc, xxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (CERA)]; XXX- xxxxxxxxx xxxxxxxxxx a xxxxxx sloučeniny, xxxx. XXXX-530, xxxxxxxxxxx.

X2.1.2 Xxxxxxxxx xxxxxxxxxx hypoxii xxxxxxxxxxxxxx xxxxxxx (HIF), např. xxxxxx; xxxxxxxxxxx (GSK1278863); XXX2; xxxxxxxxxx (XXX 85-3934); roxadustat (XX-4592); xxxxxxxxxx (XXX-6548); xenon.

S2.1.3 Xxxxxxxxxx XXXX, např. X-11706.

X2.1.4 Inhibitory xxxxxxxxxxx xxxxxxxxxxxxxxxx xxxxxxxxx faktoru xxxx (XXX-β), xxxx. xxxxxxxxxxxx; xxxxxxxxxxx.

X2.1.5 Agonisté xxxxxxxxx xxxxxxxxx receptoru, xxxx. xxxxxx XXX; xxxxxxxxxxxxx EPO (XXXX).

X2.2. XXXXXXXXX HORMONY X XXXXXX UVOLŇUJÍCÍ FAKTORY

S2.2.1 Xxxxxxx xxxxxxxxxxx xxxxxxxxxxx x mužů, mimo xxxx xxxxxx:

• xxxxxxxx xxxxxxxxxxxx (XX),

• xxxxxxxxxxxx xxxxxx (XX),

• xxxxxx xxxxxxxxxx xxxxxxxxxxxx (XxXX, xxxxxxxxxxx) x xxxx xxxxxxxxxxx analogy (xxxx. xxxxxxxxx, deslorelin, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx x xxxxxxxxxxx),

&xxxx;• xxxxxxxxxx x jeho xxxxxxxxxxx xxxxxxx.

X2.2.2 Xxxxxxxxxxxxxx x xxxxxx xxxxxxxxxx faktory, xxxx. xxxxxxxxxxxx x xxxxxxxxxxxxx.

X2.2.3 Xxxxxxx hormon (XX), xxxx xxxxxxx x xxxxxxxxx, xxxx xxxx xxxxxx:

• analogy xxxxxxxxx hormonu, xxxx. xxxxxxxxxxxxxxxxx, xxxxxxxxxxx x xxxxxxxxxx,

• xxxxxxxxx růstového xxxxxxx, např. XXX-9604 x xXX 176–191.

X2.2.4 Xxxxxxx xxxxxxxxxx xxxxxxx xxxxxx, xxxx xxxx xxxxxx:

• xxxxxx xxxxxxxxxx xxxxxxx hormon (XXXX) x xxxx analogy, xxxx. CJC-1293, XXX-1295, xxxxxxxxxx a tesamorelin,

• xxxxxxxxxxx xxxxxxxxx xxxxxxx (XXX) a jejich xxxxxxxx [xxxx. xxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx (XX-677), xxxxxxxxxx, xxxxxxxxxxx (xxxxxxx), xxxxxxxxxxx x xxxxxxxxxxx],

• xxxxxxx xxxxxxxxxx XX (XXXX) [např. xxxxxxxxxxxx, xxxxxxxxxx (xxxxxxxxx), XXXX-1, XXXX-2 (pralmorelin), GHRP-3, XXXX-4, XXXX-5 x XXXX-6].

X2.3. XXXXXXX FAKTORY X XXXXXXXXXX XXXXXXXXX XXXXXXX

Xxxx jiné xxxxxx:

• xxxxxxxxxxxxx xxxxxxx xxxxxxx (XXX)

• hepatocytový xxxxxxx xxxxxx (HGF)

• xxxxxxx xxxxxx 1 xxxxxxx xxxxxxxx (IGF-1, mecasermin) x jeho analogy

• xxxxxxxxxx xxxxxxx faktory (XXX)

• xxxxxxx xxxxxx xxxxxxxx x krevních xxxxxxxx (PDGF)

• thymosin-β4 x xxxx xxxxxxxx, xxxx. XX-500

• vaskulárně-endoteliární xxxxxxx xxxxxx (VEGF)

a xxxxx xxxxxxx xxxxxxx xxxx modulátory růstových xxxxxxx xxxxxxxxxxx xxxxxxx/xxxxxxxxx xxxxxxxx xx xxxxxxx, xxxxxxxx xxxx vazech, xxxxxxxxxxxxx, xxxxxxx xxxxxxx, xxxxxxxxxxxxx kapacitu nebo xxxxxxxxxxx xxxx xxxxxxxxx xxxxxx.

X3 XXXX-2 XXXXXXXX

XXXXXXXX XXXXX (XXX XXXXXXX X XXXX SOUTĚŽ)

Všechny xxxxxxxx xxxxx x xxxx xxxxx jsou Xxxxxxxxxx xxxxx.

Xxxxxxx selektivní x xxxxxxxxxxxx xxxx-2 xxxxxxxx xxxxxx xxxxx xxxxxxxxx xxxxxxx xxxx xxxxxxxx.

Xxxx xxxx včetně:

arformoterol

indakaterol

reproterol

tretoquinol (xxxxxxxxxxxxx)

xxxxxxxxx

xxxxxxxxxxxxxx

xxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxxx

xxxxxxxxxx

xxxxxxxxxx

xxxxxxxxxx

xxxxxxxxx

xxxxxxxxxx

xxxxxxxxxx

XXXXXXX

• Inhalační xxxxxxxxxx: xxxxxxxxx 1600 mikrogramů xx 24 xxxxx x xxxxxxxxxx xxxxxxx, xxxxxxxxxxxxxxxx 600 mikrogramů xxxxx 8 xxxxx xx xxxxxxxxx xxxxx;

• xxxxxxxxx formoterol: xxxxxxxxx xxxxxx xxxxx 54 xxxxxxxxxx xx 24 xxxxx;

• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 200 xxxxxxxxxx xx 24 hodin;

• xxxxxxxxx vilanterol: xxxxxxxxx 25 xxxxxxxxxx za 24 xxxxx.

XXXXXXXX

Xxxxxxxxxx xxxxxxxxxxx x xxxx v xxxxxxxx vyšším xxx 1000 ng/ml nebo xxxxxxxxxxx x množství xxxxxx než 40 xx/xx xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxx xxxxx x xxxx xxxxxxxxxx xx Xxxxxxxxx xxxxxxxxxxx xxxxx (XXX), xxxxx Xxxxxxxxx xxxxxxxxx kontrolovanou xxxxxxxxxxxxxxxxx xxxxxx, xx xxxxxxxxxx xxxxxxxx byl xxxxxxxxx xxxxxxxxxxxx dávky (xxxxxxxxx) xx do xxxx xxxxxxx xxxxxxxxx dávky.

S4 XXXXXXXXX A XXXXXXXXXXX XXXXXXXXXX

XXXXXXXX XXXXX (XXX XXXXXXX X MIMO XXXXXX)

Xxxxxxxx xxxxx ve xxxxxxx S4.1 a X4.2 xxxx Xxxxxxxxxx xxxxx.

Xxxxx zařazené do xxxx S4.3 a X4.4 jsou Xxxxxxxxxxxx xxxxx.

Xxxxxxxxxxx hormonové a xxxxxxxxxxx modulátory jsou xxxxxxxx.

X4.1. INHIBITORY XXXXXXXX

Xxxx xxxx včetně:

2-androstenol (5ɑ-xxxxxxx-2-xx-17-xx)

xxxxxxxx-1,4,6-xxxxx-3,17-xxxx (xxxxxxxxxxxxxxxxx)

2-xxxxxxxxxxx (5ɑ-xxxxxxx-2-xx-17-xx)

xxxxxxxx-3,5-xxxx-7,17-xxxx (xxxxxxxxx)

3-xxxxxxxxxxx (5ɑ-xxxxxxx-3-xx-17-xx)

xxxxxxxxx

3-xxxxxxxxxxx (5ɑ-xxxxxxx-3-xx-17-xx)

xxxxxxxxx

4-xxxxxxxxx-3,6,17 trion (6-xxx)

xxxxxxxx

xxxxxxxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxxx

X4.2. XXXXXXXXXXXXXX XXXXX [XXXXXXXXXXXXX A SELEKTIVNÍ XXXXXXXXXX XXXXXXXXXXXXX RECEPTORŮ (XXXXX)]

Xxxx jiné včetně:

arformoterol

indakaterol

reproterol

tretoquinol (xxxxxxxxxxxxx)

xxxxxxxxx

xxxxxxxxxxxxxx

xxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxxx

xxxxxxxxxx

xxxxxxxxxx

xxxxxxxxxx

xxxxxxxxx

xxxxxxxxxx

xxxxxxxxxx

X4.3. XXXXX XXXXXXXXXXX XXXXXXXX XXXXXXXXX XXXXXXXX XXX

Xxxx jiné xxxxxx:

xxxxxxxxxx xxxxxxxxxxxxxx aktivin A

inhibitory xxxxxxxxxx, např.:

konkurenty xxxxxxxxx xxxxxxxx IIB, xxxx.:

- xxxxx snižující xxxx xxxxxx expresi xxxxxxxxxx

- xxxxxxx xxxxxxxxx aktivinu (xxxx. XXX-031)

- proteiny xxxxxx xxxxxxxxx (xxxx. xxxxxxxxxxx, xxxxxxxxx xxxxxxxxxx)

xxxxxxxxxx xxxxx receptoru xxxxxxxx XXX (např. xxxxxxxxxx)

- xxxxxxxxxx neutralizující xxxxxxxxx xxxx xxxxxxxxxx (xxxx. xxxxxxxxxxx, xxxxxxx zumab, xxxxxxxxxxxxx, xxxxxxxxxx)

X4.4. METABOLICKÉ XXXXXXXXXX

X4.4.1 aktivátory XXX-xxxxxxxxxx xxxxxxxxxxxxx (AMPK), např. XXXXX, xxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxx aktivovaného xxxxxxxxx xxxxx (XXXXδ), xxxx. 2-(2-xxxxx-4-((4-xxxxx-2-(4- (xxxxxxxxxxxxx)xxxxx)xxxxxxx-5-xx)xxxxxxxxx)xxxxxx) xxxxxxxx xxxxxx (GW1516, XX501516) x agonisté Xxx-xxxɑ , např. XX9009, XX9011

X4.4.2 xxxxxxxx x xxxxxxxx xxxxxxxx

X4.4.3 xxxxxxxxx

X4.4.4 xxxxxxxxxxxx

X5 XXXXXXXXX X XXXXXXXXX XXXXX

XXXXXXXX STÁLE (XXX XXXXXXX X XXXX SOUTĚŽ)

Všechny xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.

Xxxxxxx xxxxxxxxx a xxxxxxxxx xxxxx, včetně xxxxx xxxxxxxxx xxxxxxx, xxxx. x- x x-, xxxx zakázány.

Mimo xxxx xxxxxx:

•&xxxx; Xxxxxxxxx, xxxx xxxx.:

xxxxxxxxxxxx; xxxxxxxx; xxxxxxxxx; xxxxxxxx; chlortalidon; xxxxxxxx xxxxxxxxxx; xxxxxxxxx; xxxxxxxxx; xxxxxxxxx; xxxxxxxxxxxxx; xxxxxxxx, xxxx. bendroflumethiazid, xxxxxxxxxxxxx x xxxxxxxxxxxxxxxxxx; xxxxxxxxx; triamteren;

• Vaptany, xxxx. xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx;

• Plazmatické expandéry xxxxxxxx xxxxxxxxxxxx, xxxx.:

xxxxxxx, xxxxxxx, xxxxxxxxxxx škrob, xxxxxxxx;

• Xxxxxxxxxxx;

• Probenecid;

a xxxxx látky s xxxxxxxx xxxxxxxxx strukturou xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

XXXXXXX

• xxxxxxxxxxx; xxxxxxxx; x xxxxxxx xxxxxxxxxxxxxx xxxxxxxx xxxxxxxxxx karboanhydrázy (xxxx. xxxxxxxxxx, brinzolamid);

• xxxxxxx xxxxxx xxxxxxxxxxx x zubní xxxxxxxxx.

XXXXXXXX

Xxxxx xxxxxxxxxxx množství xxxxx xx xxxxxxxxxx prahovým xxxxxxx: x xxxxxxxxxxx, xxxxxxxxxxx, xxxxxx, efedrinu, xxxxxxxxxxxxx x xxxxxxxxxxxxxx xx Xxxxxx Xxxxxxxxx xxxxxxxx xxxx xxxxxxxx Xxx Xxxxxxx ve xxxxxxx x diuretikem xxxx xxxxx maskovací xxxxxx (xxxxx xxxxxxxxx xxxxxx podání xxxxxxxxxx xxxxxxxxxxxxxx xxxx xxxxxxxxx xxxxxx xxxxxxxxxxx v xxxxxxxx xxxxxxxxx), xxxx xxxxxxxxx xx Xxxxxxxxx xxxxxxxxxxx xxxxx (XXX), xxxxx Xxxxxxxxx nemá xxxxxxxxxx Xxxxxxxxxxxxx xxxxxxx (XX) xx xxxx xxxxx xxxxx k xx, xxxxx již xxxx xxxxxxx xx xxxxxxxxxx xxxx xxxxx xxxxxxxxx látku.

ZAKÁZANÉ METODY

ZAKÁZANÉ XXXXX (XXX SOUTĚŽI X MIMO XXXXXX)

Xxxxxxx xxxxxxxx xxxxxx v xxxx třídě jsou Xxxxxxxxxxxx x xxxxxxxx xxxxx x M2.2, xxx jsou Specifické xxxxxx.

X1. XXXXXXXXXX X XXXX X KREVNÍMI XXXXXXXXXXXX

Xxxxxxxx je následující:

M1.1. Xxxxxx nebo xxxxxxxx xxxxxxxx xxxxxxxxxxx množství xxxxxxxxx, allogenní (xxxxxxxxx) xxxx xxxxxxxxxxx xxxx xxxx xxxxxxxx x xxxxxxxxx xxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxxx xxxxxxx s výjimkou xxxxxxxx xxxxxx xxxx xxxxxx xxxxxx Xxxxxxxxx xxxxxxxxxxxxxxx plazmaferézy provedené x xxxxxxxxxxxxx xxxxxxxxx xxxxxx.

X1.2. Xxxxx xxxxxxxxx xxxxxx, xxxxxxx xxxx xxxxxxx kyslíku.

Mimo xxxx xxxxxx:

Xxxxxxxxxxxxxxxxxxx; efaproxiral (XXX13); xxxxxxxxx a xxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx, např. xxxxxx xxxxxxxx na xxxx xxxxxxxxxxx a xxxxxxxxxxxxxxxx xxxxxxxxxxxxx produkty, x výjimkou xxxxxxxxxxx xxxxxxx xxxxxxxx.

X1.3. Xxxxxxxxx xxxxx xxxxxxxxxxxxxxx xxxxxxxxxx x krví xxxx x xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxxxx xxxxxxx.

X2. CHEMICKÁ X XXXXXXXXX MANIPULACE

Zakázané xx xxxxxxxxxxx:

X2.1. Podvádění nebo Xxxxx o podvod xx xxxxxx porušit xxxxxxxxx x xxxxxxxx Xxxxxx xxxxxxxxxx xxx Xxxxxxxxx xxxxxxxx.

Xxxx xxxx xxxxxx:

Xxxxxx a/nebo xxxxxx Xxxxxx, xxxx. xxxxxxxx xxxxxxx xx Xxxxxx.

X2.2. Xxxxxxxxxx xxxxxx a/nebo xxxxxxx xxxx xxx xxxxxx 100 xx xx 12 xxxxx xxxxx xxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxx xxxxxxxxxxxx xxxxxxxx, chirurgických xxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx.

X3. GENOVÝ X XXXXXXX XXXXXX

X xxxxxx potencionálního xxxxxxx xxxxxxxxxxx xxxxxx je xxxxxxxx xxxxxxxxxxx:

X3.1. Použití xxxxxxxxxx xxxxxxx xxxx xxxxxx xxxxxxx, xxxxx xxxxx xxxxxx xxxxxxxx xxxxxx x/xxxx exprese xxxx xxxxxxxxxx xxxxxxxxxxx. Xx xxxx jiné xxxxxxxx technologie xxxxx xxxx, xxxxxxxxx xxxx x xxxxxxxxxxx xxxxxxx xxxx.

X3.2. Xxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxx.

X6 STIMULANCIA

ZAKÁZANÉ XXX XXXXXXX

Xxxxxxx zakázané látky x xxxx třídě xxxx Xxxxxxxxxx xxxxx x výjimkou xxxxx xxxxxxxxx x X6.X, xxx xxxx Nespecifické xxxxx.

Xxxxxxxx xxxxx x xxxx xxxxx: xxxxxx x xxxxxxxxxxxxxxxxxxxxxxxx (XXXX/„xxxxxx“)

Xxxxxxx xxxxxxxxxxx, xxxxxx xxxxx xxxxxxxxx xxxxxxx, xxxx. x- x l-, xxxx xxxxxxxx.

Xxxxxxxxxxx xxxxxxxx:

X6.X: XXXXXXXXXXXX XXXXXXXXXXX

xxxxxxxxx

xxxxxxxxxxxx [4-fenylpiracetam (xxxxxxxx)]

xxxxxxxxxx

xxxxxxxxxx

xxxxxxxxx

xxxxxxxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxx

xxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxxx

xxxxxxxx

xxxxxxxxxxxxxxx

xxxxxxxxxxxx(x-)

xxxxxxxxx

x-xxxxxxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxx

xxxxxx

xxxxxxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxxxxxx

xxxxxxxxxx

xxxxxxxxx

xxxxxxxx

xxxxxxxxxx

xxxxxxxxx

xxxxxxxxx

xxxxxxxxxxx

xxxxxxxxxxx

Xxxxxxxxx, xxxxx není xxxxxxxx xxxxxx x xxxxx xxxxxx, xx Xxxxxxxxxxx xxxxxx.

X6.X: SPECIFICKÁ XXXXXXXXXXX

Xxxx xxxx xxxxxx:

2-xxxxxxxxxxx-1-xxxx (ß-xxxxxxxxxxxxxx-xxxx, XXXXX)

xxxxxxxxxxx

xxxxxxxxx

3-xxxxxxxxxx-2-xxxx (1,2-xxxxxxxxxxxxxxxxx)

xxxxxxxxxxx

xxxxxxxxx (xxxxxxxxxxxxx)

4-xxxxxxxxxxxxxxxxxx

xxxxxxxxxxx

xxxxxxx

4-xxxxxxxxxx-2-xxxx (1,3-xxxxxxxxxxxxxxx, 1,3 XXXX, xxxxxxxxxxxxxx)

xxxxxxxxxx

xxxxxxxxxxx

4-xxxxxxxxxxxx-2-xxxx (1,3-xxxxxxxxxxxxxxxxx)

xxxxxxxxxx (xxxxxxxxx)

xxxxxxxxxxx x xxxx xxxxxxxx

5-xxxxxxxxxx-2-xxxx (1,4-xxxxxxxxxxxxxxx, 1,4-dimetylpentylamin, 1,4-XXXX)

xxxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxx)

xxxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxxxxx

xxxxxxxxxxxxx

xxxxx1)

xxxxxxxxxxxxxxx

xxxxxxxxxxxxxx

xxxxxxx a xxxx xxxxxxx, xxxx. xxxxxxxx, xxxxxxxx a ɑ-xxxxxxxxxxxxxxxxxxxxxx

xxxxxxxxxxxx

xxxxxxxxxxxxx2)

xxxxxxxxxxxxxx (xxxxxxxxxxxxxxxx)

xxxxxxxxxxxxxxxxxxxxxxxx

xxxxxxxxx

xxxxxxx3)

xxxxxxxxxxxx3)

xxxxxxxxxx

xxxxxxxxx (adrenalin)4)

metylnaftidát [(±)-xxxxx-2-(xxxxxxxx-2-xx)-2-(xxxxxxxxx-2- xx)xxxxxx]

xxxxxxxxxxxx

xxxxxxxx

xxxxxxxxxxxx

xxxxxxxxx

xxxxxxxxxxx

xxxxxxxxx

xxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx)

xxxxxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxxxxxx

xxxxxxxxx

xxxxxxxx (1,5-xxxxxxxxxxxxxxxx)

x xxxxx xxxxx x podobnou xxxxxxxxx xxxxxxxxxx nebo podobnými xxxxxxxxxxxx xxxxxx

XXXXXXX

• xxxxxxxx;

• xxxxxxxx xxxxxxxxxxx v xxxxxxx xxxxxx xxxxxxx, xxxxxxx, očního nebo xxxxxx použití (xxxx. xxxxxxxxxx, xxxxxxxxxx, fenoxazolin, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxx) x xxxxxxxxxxx xxxxxxxx xx Monitorovacího programu 20245).

X7 XXXXXXXXX

XXXXXXXX XXX XXXXXXX

Xxxxxxx zakázané látky x xxxx xxxxx xxxx Specifické látky.

Návykové xxxxx v xxxx xxxxx: xxxxxxxxx (heroin)

Následující xxxxxxxxx, xxxxxx xxxxxx xxxxxxxxxx xxxxx xxxxxxxxx xxxxxxx, xxxx. x- x l, jsou xxxxxxxx.

xxxxxxxxxxx

xxxxxxxx x jeho xxxxxxxx

xxxxxx

xxxxxxxxxx

xxxxxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxxx

xxxxxxx

xxxxxxxxx (xxxxxx)

xxxxxxx

xxxxxxxx

xxxxxxxx

xxxxxxxxx

X8 KANABINOIDY

ZAKÁZANÉ XXX XXXXXXX

Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx jsou Xxxxxxxxxx xxxxx. Xxxxxxxx xxxxx x této sekci: xxxxxxxxxxxxxxxxxxx (XXX)

Xxxxxxx xxxxxxxx x syntetické xxxxxxxxxxx xxxx xxxxxxxx, xxxx.

• x xxxxxx (xxxxx, xxxxxxxxx) x xxxxxxxxx xxxxxxxxxx

• xxxxxxxx x xxxxxxxxxx xxxxxxxxxxxxxxxxxxxxx (XXX)

• xxxxxxxxxx kanabinoidy xxxxxxxxxxxx xxxxxx XXX

XXXXXXX

• xxxxxxxxxx

X9 XXXXXXXXXXXXXXX

XXXXXXXX XXX XXXXXXX

Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.

Xxxxxxx glukokortikoidy xxxx xxxxxxxx, pokud xxxx xxxxxxxx xxxxxxxxxx xxxxxxxx, perorální [xxxxxx xxxxxxxxxx (xxxx. xxxxxxx, xxxxxxxxxx, xxxxxxxxxxxx)] xxxx xxxxxxxx xxxxxx.

Xxxx jiné xxxxxx:

xxxxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxx

xxxxxxxxxxx

xxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxx

xxxxxxxxxxxx

xxxxxxxxx

xxxxxxxxxx

xxxxxxxxxx

xxxxxxxxxxxx xxxxxxxx

xxxxxxxx

xxxxxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxxxxxxxxx

XXXXXXXX

• Xxxx xxxxxxx xxxxxx (xxxxxx xxxxxxxxxxx x xxxxxxxxx: xxxxxxxx-xxxxxxxxxxxxxx, xxxxxxxxxx, intranazálního, xxxxxxxxxxxxxxxx, ušního x xxxxxxxxxxxx) xxxxxx xxxxxxxx, xxxxx se xxxxxxxxx x rámci xxxxxxxx xxxxxxxxxxxx xxxxx a xxxxxxxxxxxxxx xxxxxxxx.

X1 BETA-BLOKÁTORY

ZAKÁZANÉ X XXXXXXXX XXXXXXXX

Xxxxxxx xxxxxxxx xxxxx v xxxx xxxxx xxxx Xxxxxxxxxx látky.

Beta-blokátory jsou xxxxxxxx pouze x xxxxxxxxxxxxx sportech Při Xxxxxxx a xxx xx xx xxxxxxxx xxxxxxxx (*) x Xxxx xxxxxx.

• lukostřelba (XX)*

• xxxxxxxx/xxxxxxxxxxxx (XXX) – xxxxx xx xxxxxx, xxxxxxxxxxx xxxxx / X-xxxxx x xxxxxxxxx X-xxxxx / xxx air

• automobilový xxxxx (FIA)

• podvodní xxxxxx (XXXX)* v xxxxxxxxxxxx xxxxxxx potápění, xxxx xxxxxxxx x xxxxxxx xx xxxx

• xxxxxxxx (xxxxxxx xxxxxxxxxx) (XXXX)

• xxxxx (XXX)

• xxxx (XXX)

• xxxxxxxx (XXX)

• xxxxxxx (XXXX, XXX)*

* zakázané xxxx Xxxx xxxxxx

Xxxx jiné xxxxxx:

xxxxxxxxxx

xxxxxxx

xxxxxxxxx

xxxxxxxxxx

xxxxxxxxxx

xxxxxxxxx

xxxxxxxxxxxx

xxxxxxxx

xxxxxxxx

xxxxxxxxxx

xxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxx

xxxxxxxxxx

xxxxxxx

xxxxxxx

xxxxxxxxxx

xxxxxxx

xxxxxxxxx

xxxxxxx

Xxxxxxx x. 2

Xxxxx xxxxxxxxxxx xxxxxxx x xxxxxxxxx xxxxxx
&xxxx;

1) xxxxx (x-xxxxxxxxxxxxxxxx) x xxxx x-xxxxxx: xx xxxxxxxx xxxxx při xxxxxxxxxxx x xxxx xxxxx xxx 5 xxxxxxxxxx x 1 xx.

2) xxxxxxxxxxxxx: xxxxxxxx xxxxx xxx xxxxxxxxxxx x xxxx xxxxx než 150 xxxxxxxxxx v 1 xx.

3) xxxxxxx x metylefedrin: zakázány xxx koncentraci x xxxx vyšší než 10 xxxxxxxxxx x 1 ml.

4) xxxxxxxxx (xxxxxxxxx): xxxx xxxxxxxx xxxxxxx xxxxxxxx, např. xxxxx, xxxx, xxxx xxxxxxxx xxxxxxxx s xxxxxxxxx xxxxxxxxxx.

5) xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, kofein, xxxxxxx, pipradrol x xxxxxxxx: tyto xxxxx xxxx zahrnuté xx Xxxxxxxxxxxxxx xxxxxxxx 2024 x xxxxxx považovány xx Xxxxxxxx xxxxx.

Xxxxxxxxx

Xxxxxx xxxxxxx x. 19/2025 Sb. xxxxx xxxxxxxxx xxxx 28.1.2024.

Xxxxx xxxxxxxxxxxx právních norem xxxxxx právních xxxxxxxx x xxxxxxxx xxxx xxxxxxxxxxxxx, pokud xx xxxx netýká derogační xxxxx xxxxx uvedeného xxxxxxxx xxxxxxxx